Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure.
Previous studies have suggested the efficacy of foscarnet combined with thymidine analogues as salvage therapy in late-stage HIV-1 infection. Here, we report on the first case of foscarnet therapy in a patient infected with HIV-2 exhibiting virologic failure. The patient was known to be HIV-2-infected since 1992 and had received 11 sequential lines of combined antiretroviral therapy (cART) with almost all the available antiretroviral agents including raltegravir. A marked decrease in HIV-2 plasma viral load of 1.48 log(10)copies/ml was observed at day 14 of foscarnet induction therapy associated with zidovudine and failing cART. An optimized cART was then introduced with lamivudine, zidovudine, lopinavir/r, etravirine and maraviroc. Four months after the end of foscarnet therapy, HIV-2 plasma viral load remained undetectable. This case report suggests that foscarnet may represent a therapeutic option for HIV-2-infected patients exhibiting multidrug resistance.
Stegmann
Sophie
S
Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service d'Immunologie Clinique, Paris, France.
Manea
Maria Elena
ME
Charpentier
Charlotte
C
Damond
Florence
F
Karmochkine
Marina
M
Laureillard
Didier
D
Si-Mohamed
Ali
A
Weiss
Laurence
L
Piketty
Christophe
C
D017245:Foscarnet / Q000627:therapeutic use*; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D015498:HIV-2; D006801:Humans; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016879:Salvage Therapy / Q000379:methods*; D016896:Treatment Outcome; D019562:Viral Load
D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D017245:Foscarnet